Lv1
64 积分 2024-01-16 加入
Rationale for Fixed Dosing of Pertuzumab in Cancer Patients Based on Population Pharmacokinetic Analysis
12天前
已完结
Neoadjuvant rilvegostomig (R) + trastuzumab deruxtecan (T-DXd) in high-risk HER2-negative breast cancer: Results from the I-SPY 2.2 trial
18天前
已完结
PD-L1 protein expression in breast cancer
25天前
已完结
[Consensus on recurrence risk and clinical management of HR+/HER-2- early breast cancer (2025 edition)]
27天前
已完结
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial
1个月前
已完结
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
1个月前
已完结
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial
1个月前
已完结
Beamion BCGC-1: phase Ib/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancers
1个月前
已完结
Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer
1个月前
已完结
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
1个月前
已完结
皖公网安备34019202002308
